吸入曲前列尼尔治疗间质性肺病相关肺动脉高压的长期开放标签扩展研究
INCREASE开放标签扩展研究纳入242例间质性肺病相关肺动脉高压患者,评估吸入曲前列尼尔长期疗效与安全性。第52周平均6分钟步行距离为279.1米,较随机对照试验基线平均变化3.5米;随机对照试验中曲前列尼尔组较安慰剂组在扩展期基础肺病急性加重相对风险降低31%(HR 0.69,95%CI 0.49-0.97,P=0.03)。结果支持长期安全性和有效性。
要点
- 第52周平均6分钟步行距离279.1米,较随机对照试验基线平均变化3.5米
- 随机对照试验中曲前列尼尔组扩展期基础肺病急性加重相对风险降低31%
- 54例(22.3%)因不良事件停药,需关注长期耐受性
核心结论
- 结果支持吸入曲前列尼尔在间质性肺病相关肺动脉高压患者中的长期安全性和有效性,与INCREASE随机对照试验结果一致。
研究设计与样本
- INCREASE开放标签扩展研究,258例符合条件患者中242例入组并接受吸入曲前列尼尔治疗。
- 评估6分钟步行距离、肺功能、NT-proBNP、生活质量及不良事件,记录住院、基础肺病急性加重和死亡。
主要发现
- 扩展研究基线中位年龄70岁,平均6分钟步行距离274.2米,男性占52.1%。
- 第52周总体平均6分钟步行距离279.1米,较随机对照试验基线平均变化3.5米(既往曲前列尼尔组22.1米,既往安慰剂组-19.5米)。
- 中位NT-proBNP从随机对照试验基线389 pg·mL-1降至第64周359 pg·mL-1。
- 第64周用力肺活量较随机对照试验基线绝对变化均值51 mL(2.8%预计值)。
- 随机对照试验中曲前列尼尔组较安慰剂组在扩展期基础肺病急性加重相对风险降低31%(HR 0.69,95%CI 0.49-0.97,P=0.03)。
临床怎么用
- 对间质性肺病相关肺动脉高压患者,吸入曲前列尼尔可作为长期治疗选择,需监测基础肺病急性加重和不良事件。
局限性
- 开放标签扩展研究无同期对照组,长期疗效证据受限于随机对照试验期后的非盲设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The 16-week randomised, placebo-controlled INCREASE trial (RCT) met its primary end-point by improving 6-min walk distance (6MWD) in patients receiving inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD). The open-label extension (OLE) evaluated long-term effects of inhaled treprostinil in PH-ILD. METHODS: Of 258 eligible patients, 242 enrolled in the INCREASE OLE and received inhaled treprostinil. Assessments included 6MWD, pulmonary function testing, N-terminal pro-brain natriuretic peptide (NT-proBNP), quality of life and adverse events. Hospitalisations, exacerbations of underlying lung disease and death were recorded. RESULTS: At INCREASE OLE baseline, patients had a median age of 70 years and a mean 6MWD of 274.2 m; 52.1% were male. For the overall population, the mean 6MWD at week 52 was 279.1 m and the mean change from INCREASE RCT baseline was 3.5 m (22.1 m for the prior inhaled treprostinil arm and -19.5 m for the prior placebo arm); the median NT-proBNP decreased from 389 pg·mL-1 at RCT baseline to 359 pg·mL-1 at week 64; and the absolute (% predicted) mean forced vital capacity change from RCT baseline to week 64 was 51 mL (2.8%). Patients who received inhaled treprostinil versus placebo in the RCT had a 31% lower relative risk of exacerbation of underlying lung disease in the OLE (hazard ratio 0.69 (95% CI 0.49-0.97); p=0.03). Adverse events leading to drug discontinuation occurred in 54 (22.3%) patients. CONCLUSIONS: These results support the long-term safety and efficacy of inhaled treprostinil in patients with PH-ILD, and are consistent with the results observed in the INCREASE RCT.
引用
- Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. Eur Respir J. 2023. PMID: 37080567. doi:10.1183/13993003.02414-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。